The company is not buyable for such a low price. Missling and other BOD members will reject that, as will a very dedicated, rather large retail base. The company has legal anti takeover defenses in place and plenty of cash to keep operating.
Your assessments of 2-73 and management are about right. Small but real effect from the limited data, probably enough to eventually reach some approvals. This is what I've seen develop over the past 10 years as an investor. A few management stumbles along the way, including results disclosure.
Welcome to the board, don't mind the usual fools and flakes. What's your medical area?
News 
Market Data 
Discover 
